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LETTER TO THE EDITORDoes Extra Alemtuzumab
Remove the Graft-versus-
Leukemia Effect after
Allogeneic Stem Cell
Transplantation in Chronic
Lymphocytic Leukemia?
Three recently reported large series [1-3] used
allogeneic stem cell transplantation (allo-SCT) after
a reduced-intensity conditioning (RIC) regimen to
treat chronic lymphocytic leukemia (CLL) (Table 1).
These studies raise some important questions, includ-
ing whether or not all RIC regimens are equally effec-
tive in CLL and whether or not extra alemtuzumab,
although effective in treating CLL, removes the
graft-versus-leukemia (GVL) effect.
Delgado et al. [1] investigated outcomes in 62
patients withCLL after allo-SCTwithRIC containing
fludarabine (Flu) and melphalan (Mel) and found sim-
ilar long-term outcomes in the patients receiving alem-
tuzumab and those not receiving alemtuzumab in the
conditioning regimen. But, the interpretation of their
data is limited by the lack of comparison between pa-
tients receiving 100 mg of alemtuzumab and those re-
ceiving low-dose alemtuzumab versus those receiving
no alemtuzumab (because of the small sample size).
Moreover, 7 of the 41 patients in the alemtuzumab
group also received alemtuzumab previously as part
of CLL therapy. Data have shown that patients receiv-
ing alemtuzumab (especially at a dose of 100 mg) have
increased risk of infection, persistent disease/relapse,
and prolongedmixed chimerismnecessitating frequent
donor lymphocyte infusion (DLI) after allo-SCT
[1,2,4-6]. In contrast to Delgado et al. [1], Schetelig
et al. [2] reported poor outcomes in patients receiving
an alemtuzumab-containing RIC regimen (Table 1).
In that study, almost 90% of the patients received
RIC before undergoing allo-SCT for CLL with 17p
deletion. Poor results were reported in the alemtuzu-
mab group, despite the fact that alemtuzumab is con-
sidered the most effective therapy for CLL with 17p
deletion [7].Overall, Schetelig et al. [2] found favorable
outcomes in their patients, suggesting that theGVLef-
fect may overcome the negative prognostic impact of
17p deletion [2].
Sorror et al. [3] reported outcomes of 82 patients
who received RIC (without alemtuzumab) before un-
dergoing allo-SCT for CLL. Long-term overall sur-vival (OS) and progression-free survival (PFS) were
similar to those reported in the aforementioned series
(Table 1). Extensive chronic graft-versus-host disease
(cGVHD) occurred in more than 50% patients; the
median duration of cGVHD was 25 months (range,
12 to 61 months). More than half of the cases of non-
relapse mortality (NRM) were caused by GVHD and
associated infections. As is well known, cGVHD and
prolonged immunosuppressive therapy are also risk
factors for numerous long-term complications that
can affect late morbidity and mortality [8-11].
Rituximab as part of an RIC regimen for CD201
malignancies has demonstrated good disease control
(sparing the GVL effect) in addition to a decrease in
the rate of GVHD. Most of these data are from single-
center experiences, however [12,13].
As increasing numbers of patients are receiving
RIC before allo-SCT [13], work is needed to opti-
mize GVHD prophylaxis without compromising the
GVL effect after allo-SCT for CLL. Rituximab has
been reported to be as effective as low-dose alemtu-
zumab without compromising the GVL effect in
CLL. More patients undergoing allo-SCT have
been previously treated with alemtuzumab, leading
to the important question of whether alemtuzumab-
containing RIC regimens should be avoided in these
patients, given alemtuzumab’s prolonged T cell–
suppressing effect, which could limit the GVL effect.
This and other pertinent questions can be answered
only by enrolling more patients in multi institutional
studies.REFERENCES
1. Delgado J, Pillai S, Benjamin R, et al. The effect of in vivo T cell
depletionwith alemtuzumab on reduced-intensity allogeneic he-
matopoietic cell transplantation for chronic lymphocytic leuke-
mia. Biol Blood Marrow Transplant. 2008;14:1288-1297.
2. Schetelig J, van BA, Brand R, et al. Allogeneic hematopoietic
stem-cell transplantation for chronic lymphocytic leukemia
with 17p deletion: a retrospective European Group for Blood
and Marrow Transplantation analysis. J Clin Oncol. 2008;26:
5094-5100.
3. SorrorML, Storer BE, Sandmaier BM, et al. Five-year follow-up
of patients with advanced chronic lymphocytic leukemia treated
with allogeneic hematopoietic cell transplantation after non-
myeloablative conditioning. J Clin Oncol. 2008;26:4912-4920.
4. Delgado J, Thomson K, Russell N, et al. Results of alemtuzu-
mab-based reduced-intensity allogeneic transplantation for
chronic lymphocytic leukemia: a British Society of Blood and
Marrow Transplantation study. Blood. 2006;107:1724-1730.
5. Shore T, Harpel J, Schuster MW, et al. A study of a reduced-
intensity conditioning regimen followed by allogeneic stem
cell transplantation for patients with hematologic malignancies
using Campath-1H as part of a graft-versus-host disease strat-
egy. Biol Blood Marrow Transplant. 2006;12:868-875.517
Table 1. Allo-SCTwith an RIC Regimen in CLL
Study Number of Patients Conditioning Regimen Results Comments
Delgado et al. [1] 62 Fludarabine and melphalan
with alemtuzumab
(100 mg, n 5 23;
20-60 mg, n 5 18) or without
alemtuzumab (n 5 21).
Alemtuzumab versus
none (3-year events):
 OS, 65% versus 57%
 PFS, 39% versus 47%
 NRM, 28% versus 34%
 Relapse, 32% versus 20%
 aGVHD, 37% versus 57%
 cGVHD, 29% versus 68%
(P 5 .016).
 20 (49%) patients receiving
alemtuzumab also received
DLI for persistent mixed
chimerism and MiRD or PD.
No comparison between
patients receiving alemtuzumab
100 mg and those receiving a
lower dosage (versus those
receiving no alemtuzumab).
Schetelig et al. [2] 44  All patients had 17p deletion.
 89% received an RIC regimen.
 12 patients received alemtuzumab
before allo-SCT.
 12 patients received alemtuzumab
with graft (35- 100 mg).
 Patients receiving RIC with
alemtuzumab had poor
transplantation outcome
(OS, 22% vs 51%; PFS, 0 vs 52%;
relapse, 67% vs 19%).
 Eight of 12 patients relapsed
and 4 of 12 died of treatment-
related complications within
a median of 6 months post-SCT.
Half of the patients in the
alemtuzumab group also
received alemtuzumab
previously; it is important
to know how this group did.
Sorror et al. [3] 82 2 Gy TBI with or without
fludarabine.
 5 year: OS, 50%; PFS, 39%;
progression/relapse, 38%;
NRM, 23%.
 aGVHD grade II-IV: MRD, 55%;
MUD, 66%.
 cGVHD (ext): MRD, 49%; MUD,
53%.
 More than half of NRM was
related to GVHD and associated
infections.
MiRD indicates minimal residual disease; MUD, marrow unrelated donor; RIC, reduced-intensity conditioning; SCT, stem cell transplantation; TBI, total
body irradiation, aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; NRM, nonrelapse mortality; OS, overall survival;
DLI, donor lymphocyte infusion; PFS, progression-free survival; PD, progressive disease.
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